MENU
MEDX
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

MEDX stock forecast, quote, news & analysis

The investment seeks to provide long-term growth of capital... Show more

Category: #Health
MEDX
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for MEDX with price predictions
Aug 13, 2026

MEDX in +0.63% Uptrend, advancing for three consecutive days on August 13, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MEDX advanced for three days, in of 205 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 12, 2026. You may want to consider a long position or call options on MEDX as a result. In of 56 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MEDX just turned positive on August 10, 2026. Looking at past instances where MEDX's MACD turned positive, the stock continued to rise in of 31 cases over the following month. The odds of a continued upward trend are .

MEDX moved above its 50-day moving average on August 05, 2026 date and that indicates a change from a downward trend to an upward trend.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for MEDX entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB).

Industry description

The investment seeks to provide long-term growth of capital. The fund is an actively-managed exchange-traded fund (“ETF”) that pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries. The fund is non-diversified.

Market Cap

The average market capitalization across the Horizon Kinetics Medical ETF ETF is 134.62B. The market cap for tickers in the group ranges from 4.92M to 1.08T. LLY holds the highest valuation in this group at 1.08T. The lowest valued company is SLRX at 4.92M.

High and low price notable news

The average weekly price growth across all stocks in the Horizon Kinetics Medical ETF ETF was 25%. For the same ETF, the average monthly price growth was 56%, and the average quarterly price growth was 89%. REPL experienced the highest price growth at 18%, while LTRN experienced the biggest fall at -5%.

Volume

The average weekly volume growth across all stocks in the Horizon Kinetics Medical ETF ETF was -24%. For the same stocks of the ETF, the average monthly volume growth was -16% and the average quarterly volume growth was -28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 57
Price Growth Rating: 48
SMR Rating: 68
Profit Risk Rating: 69
Seasonality Score: -24 (-100 ... +100)
View a ticker or compare two or three
MEDX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
Listed Funds Trust490 Royal Lake DriveCape Girardeau
Phone
N/A
Web
N/A